TUCSON, Ariz., January 11, 2022 — Critical Path Institute (C-Path) is pleased to announce the Electronic Patient-Reported Outcome (ePRO) Consortium is now the Electronic Clinical Outcome Assessment (eCOA) Consortium. This rebranding more accurately reflects the expanded portfolio range of work performed by the consortium, the actual capabilities of member firms and the scope and significance of the consortium’s role. The new name was chosen to more authentically characterize the mission and aims of the consortium, which have evolved significantly since its inception in 2011.
“This name change more effectively communicates the breadth of the activities of the consortium and its members and enhances the consortium’s visibility across not just the eCOA ecosystem, but the clinical research community more broadly,” said Senior Vice President of C-Path’s COA Program, Stephen Joel Coons, Ph.D. “Rebranding as the eCOA Consortium signals an important step in the evolution of the consortium and will further facilitate multi-stakeholder discussions to identify and address the root causes of issues with eCOA implementation in clinical trials. The eCOA Consortium will continue its close collaboration with the Patient-Reported Outcome Consortium on the joint eCOA–Getting Better Together Initiative.”
Coordinated by C-Path, members of the eCOA Consortium are firms that provide electronic data collection technologies and services for capturing COA data in clinical trials. The eCOA Consortium’s mission is to advance the science of clinical trial endpoint assessment by collaboratively supporting and conducting research, designing and delivering educational opportunities and developing and disseminating best practice recommendations for electronic collection of clinical outcome data.
“This is a very necessary change that emphasizes both the substance and scope of the consortium and its output,” said Executive Director of the eCOA Consortium, Scottie Kern. “This consortium boasts not just unrivalled knowledge and experience of eCOA implementation, it has at its heart a drive to progress the science of eCOA and its criticality to modern medical product development.”
The eCOA Consortium provides a pre-competitive environment in which a critical mass of experts can collaborate to generate measurement equivalence data, develop specification documents and data standards, and provide guidance on methodological considerations related to eCOA applications. All of these activities are aimed at enhancing the quality, practicality and acceptability of electronic capture of clinical trial endpoint data.
For more information on C-Path’s eCOA Consortium, visit: https://c-path.org/programs/ecoac.
Critical Path Institute is supported by the Food and Drug Administration (FDA) of the U.S. Department of Health and Human Services (HHS) and is 54.2% funded by the FDA/HHS, totaling $13,239,950, and 45.8% funded by non-government source(s), totaling $11,196,634. The contents are those of the author(s) and do not necessarily represent the official views of, nor an endorsement by, FDA/HHS or the U.S. Government.
Critical Path Institute (C-Path) is an independent, nonprofit organization established in 2005 as a public and private partnership. C-Path’s mission is to catalyze the development of new approaches that advance medical innovation and regulatory science, accelerating the path to a healthier world. An international leader in forming collaborations, C-Path has established numerous global consortia that currently include more than 1,600 scientists from government and regulatory agencies, academia, patient organizations, disease foundations, and dozens of pharmaceutical and biotech companies. C-Path U.S. is headquartered in Tucson, Arizona and C-Path, Ltd. EU is headquartered in Dublin, Ireland, with additional staff in multiple other locations. For more information, visit c-path.org and c-path.eu.